Pharma-backed antibiotic fund makes first investments

Two years after it was first proposed and a year after it officially launched, the pharma-backed AMR Action Fund has made its first investments in companies trying to tackle the pressing pr

Venatorx plans new antibiotic filing after phase 3 readout

Venatorx Pharma has moved a step closer to what has unfortunately become a rare event in pharma – the filing of a new antibiotic designed to tackle the increasing pressing problem of

Novartis antibiotic retreat doesn’t stop Sandoz buying GSK d...

Novartis exited novel antibiotics R&D three years ago, but is clearly still interested in the category – its Sandoz unit has just spent $350 million buying GlaxoSmithKline’s cephalospor

FDA sets June date for latest review of Merck’s last-ditch a...

Merck’s last-resort antibiotic Recarbrio nears EU approval

InsightRX pens antibiotic deal for its precision dosing soft...